3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
23
Breast Neoplasms
12
Prostatic Neoplasms
11
Triple Negative Breast Neoplasms
7
Fallopian Tube Neoplasms
7
Stomach Neoplasms
5
Neoplasm Metastasis
5
Sarcoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Metastatic Castration-resistant Prostate Cancer
4
Fanconi Anemia, Complementation Group D1
4
Small Cell Lung Carcinoma
3
Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Endometrial Neoplasms
2
Interventions
3-Iodobenzylguanidine
3
cabozantinib
2
pembrolizumab
1
pazopanib
1
lutetium Lu 177 dotatate
1
guadecitabine
1
gallium Ga 68 dotatate
1
copper dotatate CU-64
1
atezolizumab
1
Sunitinib
1
Radiosurgery
1
Phenoxybenzamine
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Everolimus
1
Erlotinib Hydrochloride
1
Doxazosin
1
Axitinib
1
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Paraganglioma
×
olaparib
×
Clear all
No trials found.